Navigation Links
Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference
Date:8/25/2014

NEWARK, Calif., Aug. 25, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Morgan Stanley 2014 Global Healthcare Conference in New York City.

The presentation at the Morgan Stanley conference is scheduled for 2:40 pm ET (11:40 am PT) on Wednesday September 10, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days on the company's website.

About Depomed 
Depomed is a specialty pharmaceutical company that commercializes products for pain and CNS disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.

INVESTOR CONTACT:
August J. Moretti  
Depomed, Inc. 510.744.8000
amoretti@depomed.com


'/>"/>
SOURCE Depomed, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Depomed Reports Second Quarter 2014 Financial Results
2. Depomed Announces Appointment of R. Scott Shively as Chief Commercial Officer
3. Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014
4. Depomed Announces District Court Order in ANDA Litigation
5. Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer
6. Depomed To Present At Piper Jaffray 2013 Healthcare Conference
7. Depomed Reports Third Quarter 2013 Financial Results
8. Depomed To Report Third Quarter Fiscal Year 2013 Financial Results On Tuesday, November 5, 2013
9. Depomed Sells Type 2 Diabetes Royalties And Milestones To PDL BioPharma For $240.5 Million
10. PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
11. Depomed Expands Geographic Scope of License Agreement with Merck for Extended Release Metformin Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):